PMC:2678986 / 37206-38550 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/2678986","sourcedb":"PMC","sourceid":"2678986","source_url":"https://www.ncbi.nlm.nih.gov/pmc/2678986","text":"The HIV/AIDS pandemic has lasted almost 3 decades, and a wide range of anti-HIV drugs have been developed in an attempt to ameliorate the infection and ultimately eliminate this highly fatal disease. To tackle HIV and prevent the formation of viral sanctuary sites, antiretroviral drugs must be able to access the brain. However the normal function of the BBB and blood–CSF barrier to shield the brain from harmful substances and provide a precisely regulated unique environment in the CNS, hinders the penetration of anti-HIV drugs into the brain, promoting viral replication, the development of drug resistance and ultimately sub-therapeutic concentrations of drugs reaching the brain, leading to therapeutic failure. Consequently, Letendre's CNS penetration-effectiveness ranking concept for quantifying antiretroviral drug penetration into the CNS is clearly worthy of serious consideration as an additional tool in designing more effective drug treatment strategies (Letendre et al., 2008a). However, it is important that the actual raw information that was used to determine each drug's individual rank becomes available, so that the ranking scheme could be further and more easily enhanced by considering drug–drug interactions at the level of blood–CNS interfaces and possibly other factors (e.g. toxicity issues) as they come to light.","tracks":[]}